(Q37838439)

24 August 2017

1 reference

title

Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

24 August 2017

main subject

0 references

0 references

2

Ralf Gold

1 reference

24 August 2017

Jan Thöne

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

10 February 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

24 August 2017

published in

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

365-370

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

24 August 2017

1 reference

New drug therapies for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

From genes to function: the next challenge to understanding multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Oral laquinimod therapy in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.556618

10.1517/17425255.2011.556618

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference